Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- AGLE
- Price
- -
- Stock movement down
- -0.06 (-0.22%)
- Company name
- Aeglea Bio Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 111.75M
- Ent value
- 473.83M
- Price/Sales
- 106.03
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 116.47%
- 3 year return
- -45.84%
- 5 year return
- -33.53%
- 10 year return
- -
Last updated: 2024-12-16
DIVIDENDS
AGLE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 0.91 |
| EV to EBITDA | 3.84 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 106.03 |
| Price to Book | - |
| EV to Sales | 449.55 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 4.05M |
| EPS (TTM) | -68.57 |
| FCF per share (TTM) | -20.27 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.05M |
| Gross profit (TTM) | 1.05M |
| Operating income (TTM) | -215.55M |
| Net income (TTM) | -294.43M |
| EPS (TTM) | -68.57 |
| EPS (1y forward) | -1.84 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | -20450.76% |
| Profit margin (TTM) | -27934.72% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 90.59M |
| Net receivables | 163.00K |
| Total current assets | 205.95M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 207.26M |
| Accounts payable | 1.68M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 44.87M |
| Total liabilities | 452.67M |
| Shareholder's equity | -245.40M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -87.01M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -87.01M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -142.06% |
| Return on Invested Capital | 119.98% |
| Cash Return on Invested Capital | 35.46% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| AGLE | S&P500 | |
| Current price drop from All-time high | -90.79% | -0.08% |
| Highest price drop | -99.11% | -56.47% |
| Date of highest drop | 21 Jun 2023 | 9 Mar 2009 |
| Avg drop from high | -54.45% | -11.07% |
| Avg time to new high | 1966 days | 12 days |
| Max time to new high | 1965 days | 1805 days |
COMPANY DETAILS
Marketcap
111.75M
Marketcap category
Small-cap
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Employees
69
Website
Investor relations
-
SEC filings
CEO
Anthony G. Quinn
Country
USA
City
Austin
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner